LVCLF
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer's disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient to treat cardiovascular disease, including hypertension. It is also developing AlgaraeOS in partnership with the University of New South Wales, an artificial intelligence platform for biopharmaceutical prediction of both fixed dose combination drug targets and repurposed drug targets agnostic to medical indication. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 0.00 | $0 | -$617,966 |
| 2025 Q4 | -0.00 | $0 | -$85 |
| 2024 Q2 | -0.00 | $0 | -$700 |
| 2024 Q4 | -0.00 | $125,200 | -$514,708 |
| 2023 Q2 | -0.00 | $0 | -$1M |
| 2023 Q4 | -0.00 | $21,008 | -$833,792 |
| 2022 Q2 | -0.00 | $0 | -$1M |
| 2022 Q4 | -0.00 | $1,703 | -$1M |